Publicaciones en las que colabora con Guillermo Izquierdo Ayuso (63)

2023

  1. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

  3. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  4. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2021

  1. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

    Neurology, Vol. 96, Núm. 2, pp. e214-e227

2020

  1. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

    Multiple Sclerosis and Related Disorders, Vol. 38

  2. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

  3. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

    PLoS ONE, Vol. 15, Núm. 4

2019

  1. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243

  2. Recomendaciones de uso de cladribina comprimidos en la esclerosis múltiple recurrente

    Revista de neurologia, Vol. 69, Núm. s02, pp. 1-9

  3. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  4. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

  5. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)

    Multiple Sclerosis and Related Disorders, Vol. 29, pp. 7-14

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Neurology, Vol. 89, Núm. 10, pp. 1050-1059

  2. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  3. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203

  4. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

  5. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84